Cargando…
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus
BACKGROUND: A vaccine (HB-101) consisting of 2 nonreplicating lymphocytic choriomeningitis virus (LCMV) vectors expressing the human cytomegalovirus antigens glycoprotein B (gB) and the 65-kD phosphoprotein (pp65), respectively, is in development to prevent cytomegalovirus infection. METHODS: HB-101...
Autores principales: | Schwendinger, Michael, Thiry, Georges, De Vos, Beatrice, Leroux-Roels, Geert, Bruhwyler, Jacques, Huygens, Ariane, Ganeff, Corinne, Buchinger, Heidemarie, Orlinger, Klaus K, Pinschewer, Daniel D, Monath, Thomas P, Lilja, Anders E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016443/ https://www.ncbi.nlm.nih.gov/pubmed/32313928 http://dx.doi.org/10.1093/infdis/jiaa121 |
Ejemplares similares
-
1531. A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 Is Safe and Immunogenic in Healthy Volunteers, Allowing for Development of a Phase II Clinical Trial in Living Donor Kidney Transplant Recipients
por: Kotton, Camille Nelson, et al.
Publicado: (2018) -
Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2023) -
Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer
por: Schmidt, Sarah, et al.
Publicado: (2020) -
Immunity to Cytomegalovirus in Early Life
por: Huygens, Ariane, et al.
Publicado: (2014) -
Characterization of host proteins interacting with the lymphocytic choriomeningitis virus L protein
por: Khamina, Kseniya, et al.
Publicado: (2017)